RCMNY
TVRD

Rubric Capital Management (New York)’s Tvardi Therapeutics TVRD Stock Holding History

Rubric Capital Management (New York)’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7,416
Closed -$2.5M – 103
2022
Q3 		$2.5M Hold
7,416
– – 0.13% 75
2022
Q2 		$2.44M Buy
+7,416
New +$2.6M 0.13% 76

Other funds holding TVRD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Rubric Capital Management (New York)'s TVRD Position: Q4 2022 in Review

Rubric Capital Management (New York) sold out of Tvardi Therapeutics (TVRD) in Q4 2022, closing a stake of 7,416 shares — an estimated $2.5M sold.

Rubric Capital Management (New York) first reported a position in TVRD in Q2 2022 and held it in 2 quarters. The position peaked at $2.5M in Q3 2022. 160 funds tracked by Wall St. Rank hold TVRD as of Q4 2022.

  • Rubric Capital Management (New York) reported no remaining Tvardi Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 7,416 Tvardi Therapeutics shares in Q4 2022, an estimated $2.5M.
  • Rubric Capital Management (New York) first reported a position in Tvardi Therapeutics in Q2 2022 and held it in 2 quarters.
  • Rubric Capital Management (New York)'s Tvardi Therapeutics position peaked at $2.5M in Q3 2022.
  • 160 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2022.

Based on Rubric Capital Management (New York)'s 13F filing for Q4 2022, filed 10 Feb 2023.